Official websites use. Share sensitive information only on official, secure websites. Corresponding author: Anne-Laure Borel, alborel chu-grenoble. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.
Continuous glucose monitoring CGM combined with continuous subcutaneous insulin infusion CSII achieves better glycemic control than multi-injection therapy in people with type 2 diabetes.
The effectiveness of closed-loop therapy needs to be further evaluated in this population. Secondary outcomes were other CGM-glucose metrics, physical activity, and sleep objectively measured using 1-week actimetry.
Data were analyzed using a modified intention-to-treat approach. Mean HbA 1c at inclusion was 7. TIR increased to Analyses of secondary end points showed a decrease in time above range, in glucose management indicator, in glucose variability, and an increase in daily insulin dose. Actimetric sleep analysis showed an improvement in sleep fragmentation during closed-loop treatment. The prevalence of type 2 diabetes has risen steadily since the s.
The International Diabetes Federation estimated that in , million people in the world had diabetes, and this number is projected to reach million by and million by 1. People who live with type 2 diabetes have a higher risk of organ dysfunction and failure, especially the kidneys, eyes, and nerves. Type 2 diabetes is a progressive disease.
